The horse left some time ago. The stable door is now the subject of an extensive research programme, a series of clinical trials, a funding application to determine the most evidence-based method of closing it, and a pilot study to evaluate whether a pill might make the horse less interested in leaving in the first place.
The pharmaceutical pursuit of a loneliness treatment is not surprising given the trajectory that preceded it. Once the chronic disease framing was established—once loneliness had been successfully positioned as a clinical condition with measurable health consequences amenable to evidence-based intervention—the pharmaceutical question followed as naturally as it follows from any chronic disease framing.
Chronic diseases have treatments. Treatments, in the current healthcare paradigm, include pharmacological options. The question of whether a pill could address the neurobiological correlates of chronic loneliness is the logical next step from a framing that positioned loneliness as a neurobiological condition in the first place.
The trials are real. Researchers at the University of Chicago have tested oral pregnenolone—a neurosteroid—on young, healthy people who report chronic loneliness. The mechanism being targeted is social hypervigilance: the tendency, identified in chronically lonely people, to perceive social interactions as threatening, to monitor the social environment for signs of rejection with the kind of continuous alertness that makes genuine connection difficult because genuine connection requires the occasional suspension of monitoring. The pregnenolone is intended to reduce this hypervigilance—to lower the threat response that the social environment generates in people who have learned, through experience of isolation, to expect rejection from it.
The intention is not cynical. The researchers studying social hypervigilance have identified something real: the chronic loneliness that produces the health consequences the epidemic literature documents is not simply the absence of social contact. It is a state in which the nervous system has been calibrated by experience to treat the social environment as threatening, which makes the pursuit of connection costly and its achievement difficult. The lonely person is not merely without connection. They are in a state in which connection has become associated with danger, and the biological system that is supposed to enable connection is running in a mode that inhibits it.
The pregnenolone trial addresses this state by attempting to recalibrate the threat response chemically. The person takes the pill. The pill reduces the activity of the neural systems associated with social threat detection. The reduced activity makes the social environment feel less threatening. The less threatening social environment makes the pursuit of connection less costly. The less costly pursuit of connection makes connection more likely to occur.
This is the mechanism. It is a real mechanism addressing a real neurobiological state. What it does not address is the environment that produced the state. The chronic loneliness that has calibrated the nervous system toward hypervigilance was produced by sustained experience of an environment that failed to provide the connection the nervous system requires. That environment—the lonelygenic suburb, the managed workplace, the slow space that closed, the weak tie that had no occasion to form—is unchanged by the pregnenolone. The person takes the pill, enters the social environment with a reduced threat response, and encounters the same environment that produced the hypervigilance in the first place. The pill has changed the person’s relationship to the environment. The environment has not changed.
The oxytocin trials are working at a different point in the same mechanism. Intranasal oxytocin administered before or during group therapy sessions to augment positive bonding responses—to produce, chemically, the feeling of trust and connection that the session is attempting to generate through its content. The oxytocin does not create the relationship. It creates the neurochemical conditions that make relationship feel possible in the session in which it is administered. Whether the feeling persists after the oxytocin clears, whether the bonds formed under its influence are maintained in the absence of the chemical, whether the person’s nervous system learns from the chemically augmented experience or returns to its default calibration when the augmentation is withdrawn—these are the questions the trials are working to answer.
The questions are genuine. The answers are not yet available. What is already available is the observation that the question being asked—can we chemically produce the neurobiological state that genuine connection produces, in the absence of the genuine connection that would otherwise produce it—is a question that only becomes necessary to ask if the genuine connection is unavailable and its unavailability is accepted as a given rather than as a condition to be changed.
The green prescription sits at the other end of the intervention spectrum and illustrates the same structural problem from a different angle. The doctor who prescribes time in nature is responding to evidence that exposure to natural environments reduces cortisol levels, lowers heart rate, reduces the activity of the prefrontal cortex associated with rumination, and produces the kind of physiological regulation that the pregnenolone is attempting to produce chemically. The evidence is real. The prescription is responding to something genuine.
The green prescription and the pregnenolone trial are, despite their apparent opposition, structurally similar. Both are medical interventions, delivered through a clinical framework, targeting the individual’s neurobiological state rather than the environment that produced it. Both keep the response within the clinical loop—the doctor, the prescription, the monitored outcome. Both treat the person as a patient whose physiological dysregulation requires professional management. Neither addresses the conditions that produced the dysregulation. One proposes to manage it chemically. The other proposes to manage it botanically.
The management is the shared feature. The structural cause is the shared absence.
The situation these trials make visible is not of the researchers pursuing them, working within the constraints of the framework that the chronic disease framing has produced and addressing real neurobiological states with genuine scientific care. The situation has made their work necessary—or rather, has made the question they are pursuing seem more tractable than the question they are not pursuing.
We have found it easier to investigate the recalibration of the human brain’s social threat response than to investigate the recalibration of the environments that produced the miscalibration. This is not because the environmental recalibration is technically impossible. Finland has produced evidence that housing policy can address the structural conditions of isolation. Walkable urban design has produced evidence that built environment affects the frequency of incidental encounter. The slow space has produced evidence, where it has been studied, that the conditions it creates are associated with genuine connection. The evidence is available.
The evidence is available and is not funded at the scale at which the neurological trials are funded because the neurological trial produces a patent. The patent produces a product. The product produces revenue. The revenue funds the next trial. The environmental intervention produces a changed neighbourhood. The changed neighbourhood produces the conditions for connection that the nervous system was calibrated by evolution to expect. The changed neighbourhood does not produce a patent.
The chemical band-aid is the terminus of a journey that began when the subjective internal experience of isolation was reclassified as a chronic disease risk factor amenable to clinical intervention. Each step along the journey followed logically from the previous one. The chronic disease framing produced the clinical management approach. The clinical management approach produced the outcome measures calibrated to clinical improvement. The clinical improvement paradigm produced the question of whether pharmacological intervention could accelerate the improvement. The pharmacological question produced the trials. The trials are producing findings. The findings will produce recommendations. The recommendations will produce prescriptions.
The lonelygenic suburb will not appear in the prescription.
The prescription will be filled at the pharmacy in the suburb that has no local pub, no community centre, no walkable street, no slow space within accessible distance, no weak ties forming in the queue that no longer exists because the delivery app has replaced the errand.
The person will take the pill.
The pill will reduce the threat response.
The environment will remain.
The stable door research programme is fully funded.
The field that the horse is in has not been mapped.
The mapping would not produce a patent.
The Vorpel Foundation